Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

February 9th 2020

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Immunotherapy Shows Promise in Cervical Cancer Treatment

February 9th 2020

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

February 9th 2020

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

Novel PARP Combinations Boost Responses in Ovarian Cancer

February 9th 2020

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

PARP Inhibitors May Have Benefit in BRCA-Mutant Endometrial Cancers

February 8th 2020

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial Cancer

February 8th 2020

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer

February 7th 2020

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian Cancer

February 7th 2020

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

Niraparib Emerges as a Frontline Maintenance Standard in Advanced Ovarian Cancer

February 6th 2020

Antonio González-Martín, MD, discusses the design and findings of the PRIMA trial in advanced ovarian cancer.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer

January 29th 2020

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

January 29th 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Dr. Taylor on Molecular Testing Recommendations in Ovarian Cancer

January 29th 2020

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Dr. Fowler on Selection Criteria for Surgical Procedures in Ovarian Cancer

January 29th 2020

Jeffrey M. Fowler, MD, discusses selection criteria that can help determine which surgical procedure to pursue in ovarian cancer.

Dr. Boisen on Neoadjuvant Chemotherapy Versus Upfront Surgery in Ovarian Cancer

January 29th 2020

Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.

Frontline Veliparib Regimen Viable Approach in Advanced Ovarian Cancer

January 28th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the VELIA trial and the impact the results are going to have on the use of PARP inhibitors in ovarian cancer.

Dr. Orr on Ongoing Biomarker Research in Ovarian Cancer

January 28th 2020

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Dr. Salani on Patient Selection for Primary Debulking Surgery in Ovarian Cancer

January 25th 2020

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.